markets.businessinsider.com Open in urlscan Pro
151.101.64.64  Public Scan

Form analysis
3 forms found in the DOM

GET https://markets.businessinsider.com/searchresults?_search=/

<form action="https://markets.businessinsider.com/searchresults?_search=/" method="GET">
  <div class="styled-input text-input search-mi search-masthead">
    <input id="" name="_search" class="search-box-input search-mi search-masthead headline-regular" value="" placeholder="Search markets" autocomplete="off" type="text" autocapitalize="on">
    <div class="floating-label headline-regular">Search markets</div>
    <div class="x-svg-icon"></div>
    <span id="" class="error headline-regular" for="_search"></span>
    <svg class="svg-icon search-icon-new search-mi search-masthead" role="img" xmlns="http://www.w3.org/2000/svg" width="1em" height="1em" viewBox="0 0 16 16">
      <title>Search icon</title>
      <desc>A magnifying glass. It indicates, "Click to perform a search".</desc>
      <g class="search-icon-new-path" stroke="#111" stroke-width="2" fill="none">
        <path stroke-linecap="square" d="M14.6,14.5l-4.2-4.2"></path>
        <circle cx="6.4" cy="6.4" r="5.4"></circle>
      </g>
    </svg> <input type="submit" value="Press here to search" class="search-button search-mi search-masthead" data-analytics-product-module="masthead" data-analytics-product-area="search">
  </div>
  <div class="search-dropdown-wrapper search-mi search-masthead" data-component-type="markets-insider/search-box-dropdown">
    <div class="dropdown-inner-wrapper"></div>
  </div>
</form>

GET /searchresults?_search=/

<form action="/searchresults?_search=/" method="GET">
  <div class="styled-input text-input search-mi search-full-width">
    <input id="" name="_search" class="search-box-input search-mi search-full-width headline-regular" value="" placeholder="Search markets" autocomplete="off" type="text" autocapitalize="on">
    <div class="floating-label headline-regular">Search markets</div>
    <div class="x-svg-icon"></div>
    <span id="" class="error headline-regular" for="_search"></span>
    <svg class="svg-icon search-icon-new search-mi search-full-width" role="img" xmlns="http://www.w3.org/2000/svg" width="1em" height="1em" viewBox="0 0 16 16">
      <title>Search icon</title>
      <desc>A magnifying glass. It indicates, "Click to perform a search".</desc>
      <g class="search-icon-new-path" stroke="#111" stroke-width="2" fill="none">
        <path stroke-linecap="square" d="M14.6,14.5l-4.2-4.2"></path>
        <circle cx="6.4" cy="6.4" r="5.4"></circle>
      </g>
    </svg> <input type="submit" value="Press here to search" class="search-button search-mi search-full-width" data-analytics-product-module="masthead" data-analytics-product-area="search">
  </div>
  <div class="search-dropdown-wrapper search-mi search-full-width" data-component-type="markets-insider/search-box-dropdown">
    <div class="dropdown-inner-wrapper"></div>
  </div>
</form>

POST /news/searchresults

<form class="grid__row" id="newsSearchForm" action="/news/searchresults" method="post">
  <div class="grid__col--12 header-underline"> Find News <a href="/news" class="header-underline__right-text">News<span class="icon icon-arrow-right"></span></a>
  </div>
  <div class="grid__col--10 padding-right--xsmall">
    <input type="text" name="_newsSearchTerm" class="text-input text-input--stretch" placeholder="Search Text">
  </div>
  <div class="grid__col--2 padding-left--xsmall">
    <button class="button button--primary button--stretch">GO</button>
  </div>
</form>

Text Content

Menu icon A vertical stack of three evenly spaced horizontal lines.
Business Insider logo The words "Business Insider"
Markets Insider logo The word "Markets Insider".
Search markets

Search icon A magnifying glass. It indicates, "Click to perform a search".

My Watchlist
Markets Stocks Indices Commodities Cryptocurrencies Currencies ETFs News
Calendar icon An icon in the shape of a calendar.
Economic Earnings
Search markets

Search icon A magnifying glass. It indicates, "Click to perform a search".

Search icon A magnifying glass. It indicates, "Click to perform a search".
Markets Insider logo The word "Markets Insider".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an
interaction, or dismiss a notification.
 * 
   Markets The word Markets
   * Bonds
   * Funds
   * Pre-Market
   * Market Movers
   * Dow Jones Live
   * Your Portfolio
 * 
   Stocks The word Stocks
   * Stocks Finder
   * Market Movers
   * Index Constituents
   * Earnings Calendar
   * Dividends
 * 
   Indices The word Indices
   * Market Movers
   * Index Constituents
   * Dow Jones Live
   * S&P 500 Live
   * Nasdaq Live
   * World Map
 * 
   Commodities The word Commodities
   * News
   * Commodities Live
   * Gold
   * Oil
   * Copper
 * 
   Cryptocurrencies The word Cryptocurrencies
   * Bitcoin
   * Ethereum
   * Cryptocurrencies Live
 * 
   Currencies The word Currencies
   * News
   * Currencies Live
   * Currency Converter
   * EUR/USD
   * GBP/USD
   * US Dollar Index
 * 
   ETFs The word ETFs
   * News
   * ETF Finder
   * ETF Issuers
 * News The word News

My Watchlist
My Watchlist
Facebook Icon The letter F. Twitter icon A stylized bird with an open mouth,
tweeting. LinkedIn icon The word "in". YouTube icon A play button in the shape
of a television screen. Instagram icon A stylized camera.
Business Insider logo The words "Business Insider"
 * © 2024 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved.
 * Registration on or use of this site constitutes acceptance of our Terms of
   Service and Privacy Policy.

 * Disclaimer
 * Accessibility
 * Commerce Policy
 *  
 * Advertising Policies
 * Made in NYC
 * Stock quotes by  finanzen.net

Pre-Market Futures

DOW FUTURES

+0.05%

+20.00

38,632.00



S&P 500 FUTURES

-0.38%

-18.75

4,932.25



NASDAQ 100 FUTURES

-0.79%

-138.50

17,450.00



gold

-0.11%

-2.21

2,034.79



oil (wti)

-0.27%

-0.21

77.61



BTC/USD

+0.06%

+26.02

42,937.98

Close icon Two crossed lines that form an 'X'. It indicates a way to close an
interaction, or dismiss a notification.
 * Home
 * Stocks
 * Alkermes-stock
 * News for Alkermes Alkermes
 * Buy Rating Affirmed on Alkermes’s Stock Amid Strong Earnings and Positive
   2024 Outlook


BUY RATING AFFIRMED ON ALKERMES’S STOCK AMID STRONG EARNINGS AND POSITIVE 2024
OUTLOOK




TipRanks
Jan. 25, 2024, 11:48 PM










Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on Alkermes
(ALKS – Research Report). The associated price target is $35.00.

Uy Ear of Mizuho Securities has given a Buy rating to Alkermes’s stock based on
an anticipated earnings beat and positive 2024 guidance expectations. For the
fourth quarter of 2023, Ear expects Alkermes to surpass consensus estimates on
both revenue and earnings per share, primarily due to strong manufacturing and
royalty revenues. Although there may be some softness in sales of proprietary
products like Vivitrol, Aristada, and Lybalvi, this has been foreseen through
weekly prescription volume data. Ear maintains confidence in the stock with an
unchanged price target of $35 following a comprehensive model update.
Looking ahead to 2024, the analyst projects that Alkermes will exceed consensus
revenue and non-GAAP earnings per share estimates. This outlook is bolstered by
management’s accelerated profitability targets and a commitment to a roughly 30%
EBITDA margin, which were initially set to be achieved later. Despite the
stock’s underperformance and investor skepticism regarding the feasibility of
these targets, Ear believes that the strong guidance provided by Alkermes,
especially for their proprietary products, suggests potential for an earnings
upside. Hence, the sustained Buy rating reflects an anticipation of Alkermes’s
ability to outperform market expectations and achieve their profitability goals.

Ear covers the Healthcare sector, focusing on stocks such as Arcutis
Biotherapeutics, ACADIA Pharmaceuticals, and Neurocrine. According to TipRanks,
Ear has an average return of 4.1% and a 41.09% success rate on recommended
stocks.

In another report released on January 16, Piper Sandler also reiterated a Buy
rating on the stock with a $35.00 price target.

See today’s best-performing stocks on TipRanks >>






TipRanks tracks over 100,000 company insiders, identifying the select few who
excel in timing their transactions. By upgrading to TipRanks Premium, you will
gain access to this exclusive data and discover crucial insights to guide your
investment decisions. Begin your TipRanks Premium journey today.



Alkermes (ALKS) Company Description:

Alkermes Plc is a biopharmaceutical company, which engages in the development,
research, and commercialization of medicines that are designed to address unmet
medical needs of patients in major therapeutic areas. Its products include
Aristada, which is used for the treatment of schizophrenia in adults; and
Vivitrol, which is an injectable medication for the treatment of alcohol
dependence and for the prevention of relapse to opioid dependence, following
opioid detoxification. The company was founded on May 4, 2011 and is
headquartered in Dublin, Ireland.






Read More on ALKS:

 * Alkermes reports results from Phase 3 study of LYBALVI
 * Alkermes price target raised to $29 from $27 at BofA
 * Alkermes, Armstrong World, National Healthcare, PJT Partners to join S&P 600
 * Alkermes to sell manufacturing facility in Ireland to Novo Nordisk for $92.5M
 * Alkermes weakness on Jazz pause a buying opportunity, says Mizuho




SHARE THIS POST

FACEBOOK
TWITTER
EMAIL
COPY LINK







ALKERMES NEWSMORE



Alkermes Buy Rating Affirmed: Profitability and Expansion in Neuroscience Poised
for Growth
TipRanks 1d
Buy Rating Affirmed on Alkermes’s Stock Amid Strong Earnings and Positive 2024
Outlook
TipRanks 5d
The 3 Most Undervalued Biotech Stocks to Buy in January
InvestorPlace 15d
Alkermes Poised for Growth: Strong Sales and Promising Pipeline Justify Buy
Rating
TipRanks 20d
Alkermes: Strong Buy Rating Amidst Robust 2024 Outlook and Promising OX2
Franchise Prospects
TipRanks 22d
Alkermes Reports Results From Long-Term Safety And Durability Of Treatment
Effect Study Of LYBALVI
RTTNews 28d
Analysts Offer Insights on Healthcare Companies: Green Thumb Industries
(OtherGTBIF), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)
TipRanks 28d
Decoding 5 Analyst Evaluations For Alkermes
Benzinga 28d



Start Trading >>
Plus500. 81% of retail CFD accounts lose money

Your Market View

Name Price +/- % Date TSLA 186.70 -4.89 -2.55 Official Close 1/30/2024 AAPL
187.39 -0.65 -0.35 Official Close 1/30/2024 MSFT 407.65 -0.94 -0.23 Official
Close 1/30/2024 NFLX 561.75 -1.10 -0.20 Official Close 1/30/2024 SPOT 217.00
-0.58 -0.27 Official Close 1/30/2024















RELATED STOCKS


ALKS
27.41
-0.90 (-3.18%)
1/30/2024

Disclaimer
Get real-time ALKS charts here >>




Find News News

GO



Follow us on:


See also:


Indices

 * Dow Jones
 * S&P 500
 * Nasdaq 100
 * Nasdaq Composite
 * FTSE 100
 * Nikkei 225
 * DAX 40
 * Hang Seng
 * Kospi
 * S&P TSX Composite Index
 * ASX
 * US Dollar Index
 * Stock Indices
 * Dow Futures
 * Dow Jones Market Movers

Commodities

 * Gold Price
 * Oil Price
 * Silver Price
 * Copper Price
 * Cotton Price
 * Heating Oil Price
 * Aluminum Price
 * Natural Gas Price
 * Realtime Commodity Prices

Currencies

 * EURO DOLLAR
 * Bitcoin Price
 * ETH USD
 * CAD USD
 * PESO USD
 * POUND USD
 * USD INR
 * Currency Converter
 * Exchange Rates

Stocks

 * Google Stock
 * Meta Stock
 * Amazon Stock
 * Tesla Stock
 * Dow-Stock
 * Premarket
 * Stock Market News

See more - Explore more categories
 * *© 2024 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved.
   Registration on or use of this site constitutes acceptance of our  Terms of
   Service and Privacy Policy.

 * Disclaimer
 * Accessibility Statement
 * Commerce Policy
 * Advertising Policies
 * Made in NYC
 * Stock quotes by finanzen.net
 *  
 * Contact Us
 * Masthead

Your Privacy Choices